Kyowa Kirin Acquires Orchard Therapeutics
October 5, 2023
Kyowa Kirin Co., Ltd. agreed to acquire Orchard Therapeutics plc for $16.00 per ADS in cash plus a $1.00 contingent value right (CVR), representing a potential total equity value of approximately $477.6 million. The acquisition gives Kyowa Kirin a leading HSC gene therapy platform and commercial asset Libmeldy, accelerating development and commercialization of Orchard's rare-disease gene therapies.
- Buyers
- Kyowa Kirin Co., Ltd.
- Targets
- Orchard Therapeutics plc
- Sellers
- Orchard Therapeutics shareholders
- Industry
- Biotechnology
- Location
- England, United Kingdom
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.